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ABSTRACT: Here we describe the construction of an integrated and pH-sensitive nanomachine 
with layer-by-layer supramolecular design and enzymatic control for on- command delivery. The 
nanodevice comprises a first layer of β-cyclodextrin-coated gold nanoparticles as capping 
element of benzimidazole functionalized mesoporous silica nanoparticles, and a second control 
layer based on an adatamantane-modified glucose oxidase derivative. The nanomachine was 
selectively fuelled by glucose and successfully employed for the autonomous release of 
doxorubicin in HeLa cancer cells 
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Nowadays, the development of smart nanomachines able to perform sensing and actuating 
tasks in an autonomous and programmed way is a major scientific challenge because of their 
potential applications.1−3 Among other uses, these novel nanomachines  could  be  employed  to  
design  more effective drug delivery systems, sensitive sensors, and nanostructured devices for 
pathogen control and environmental protection.4−7 In the field of drug delivery, mesoporous 
silica nanoparticles (MSN) have been largely employed as nanosized scaffold.8−10 This fact has 
been supported by their high loading capacity, low toxicity, high specific volume, and easy 
preparation with controlled pore and nanoparticle morphology and dimensions.11 Moreover, 
MSN can be rationally modified at their surface with stimulus-responsible molecular, 
biomolecular, or supramolecular ensembles, producing integrated nanocarriers able to release 
their cargo in response to external physical, chemical, or biochemical stimuli.12−15 However, 
despite the description of a large number of MSN mechanized with original gatelike ensembles 
for controlled delivery,8−15 the design of integrated autonomous nanodevices able to selectively 
deliver their cargo in the presence of simple molecular stimuli has barely been explored. 
In previous works, we proposed the use of immobilized enzymes as biochemical units to control 
MSN-based nano- machines.6,16−21 These biocatalysts can act as sensing element able to detect 
the presence of target compounds in the environment which are recognized as enzyme 
substrates (INPUT signal). Enzymes catalyze their conversion to specific molecules than act as 
local “chemical messengers” able to operate the stimulus-responsible ensembles in the 
functionalized MSN nanocarrier allowing cargo release (OUTPUT signal). This hypothesis was 
successfully demonstrated by using enzymes or combination of enzymes acting as Boolean logic 
gates to control the release from gated MSN and mesoporous Janus nanoparticles.22,23 
With the aim of advancing the preparation of more complex enzyme-containing nanodevices for 
smart delivery, we describe here an enzyme-controlled MSN nanomachine with a layer-by- layer 
supramolecular architecture. The core of this nanocarrier is based on MSN loaded with a 
selected cargo (see Scheme 1). 
 
Scheme 1. Architecture and performance of the enzyme-controlled nanomachine upon addition of glucose, which is 
transformed to gluconic acid by Gox-ADA, disrupting the pH-sensitive nanovalves and inducing cargo delivery. 
This nanoparticle was then functionalized with benzimida- zole moieties able to form pH-
sensitive host−guest complexes with a first layer of β-cyclodextrin coated Au nanoparticles 
(AuCD),24,25 acting as gatelike nanovalve and double supramolecular bridge. Then, a second layer 
of adamantane-modified glucose oxidase (GOx-ADA)16 was further immobilized by 
supramolecular association with the exposed β-cyclodextrin residues at the Au nanoparticle 
surface. This engineered nanomachine was able to release the cargo in an autonomous way 
upon addition of glucose, and was successfully evaluated as smart delivery system for an 
anticancer drug in in vitro and ex vivo experiments. 
Scheme 2 represents the experimental steps involved in the assembly of the glucose-responsive 
nanomachine. MSN was first prepared by hydrolysis and condensation of tetraethyl orthosilicate 
in alkaline media using the surfactant cetyltrimethylammonium bromide as a porogenic agent.17 
The starting mesoporous nanoparticles (solid S0) was then obtained after removal of the 
surfactant molecules by calcination in air at high temperature. In a second step, S0 was loaded 
with tris(bipyridine)ruthenium(II)  chloride   ([Ru(bpy)3]Cl2)   to act as reporter dye, and the 
hydroxyl groups at the external nanoparticle’s surface were reacted with 3-iodopropyltrime- 
thoxysilane. To construct the pH-sensitive gatelike scaffolding, we then grafted benzimidazole 
molecules to 3-iodopropyl moieties through a nucleophilic substitution reaction, generating a 
nanoparticle modified with 1-propyl-1-H-benzimidazole residues (solid S1).16 
In parallel, per-6-thio-6-deoxy-β-cyclodextrin was synthesized as previously described25 to 
further prepare AuCD (ca. 3−5 nm) by reduction of HAuCl4 with NaBH4 in the presence of the 
cyclodextrin derivative.24,25 This nanoparticle was layered on the S1 surface by simple incubation 
in aqueous media with AuCD, yielding the solid S2. 
 
Scheme 2. Experimental steps involved in the assembly of the Gox-controlled nanomachine S3. MSN (S0) was filled 
with [Ru(bpy)3]Cl2 and further modified with 3-iodopropyltrimethoxysilane and benzimidazole to yield S1. Capping 
with AuCD leads to solid S2, which was then functionalized with GOx-ADA derivative via host−guest interactions to 
produce S3. 
 
Figure 1. Representative TEM images of solids S0, S1, and S2. 
These intermediate supports (S0, S1, and S2 nanoparticles) were characterized by different 
techniques. TEM analysis revealed a spherical shape with average diameter of 110 ± 7 nm and 
the characteristic pore morphology of MCM-41 for all mesoporous silica nanoparticles (Figure 
1). In addition, the presence of AuCD homogeneously attached to the mesoporous silica 
nanoparticle surface in solid S2 was clearly evidenced. 
The X-ray diffraction analysis of all intermediate adducts are shown in Figure 2A. All solids 
showed a peak around 2.6° corresponding to the (100) Bragg reflection of MCM-41 materials 
with d-spacing values of 3.40 nm.17 This fact suggests a mesoporous order in these 
nanomaterials, which was not affected by the different modification and dye loading processes. 
On the other hand, the diffraction pattern of solid S2 at high angles revealed the cubic gold 
characteristic (111), (200), (220) and (311) diffraction peaks,26 confirming the presence of AuCD 
colloids in this nanodevice as previously observed by TEM. The presence of AuCD in S2 was also 
confirmed by the broad absorption band around 570 nm in the UV−vis spectrum (Figure S1). 
 
Figure 2. (A) Powder X-ray patterns and (B) N2 adsorption (closed)/desorption (open) isotherms for S0, S1, and S2 
nanoparticles. 
The N2 adsorption/desorption isotherms of all intermediate supports are shown Figure 2B. Solid 
S0 showed the typical type IV isotherms of MCM-41 mesoporous nanoparticles, with a BET 
specific surface of 1053 m2/g an average pore size of ca. 2.2 nm (see Figure S2). On the contrary, 
solid S1 showed the characteristic N2 adsorption/desorption isotherms of meso- porous 
materials with filled pores, and accordingly, no appreciable porosity was observed. This pattern 
indicates high load of [Ru(bpy)3]Cl2 into the mesopores of the nanoparticles. The BET specific 
surface value for this filled nanomaterial was estimated as 19 m2/g. Solid S2 showed similar 
behavior, but some N2 adsorption was observed at high relative pressure values, suggesting that 
some pores were partially emptied because of the release of some [Ru(bpy)3]Cl2 molecules 
during the capping process with AuCD. The BET specific surface of this capped solid was 
calculated as 143 m2/g. FT-IR spectroscopy was also employed to characterize these 
nanomaterials. As can be observed in Figure S3, solid S0 showed the characteristics spectra of 
siliceous materials,22 with adsorption bands at 4570, 573, 807, 951, and 1085 cm−1 attributed to 
the Si−O, Si−O−Si, SiO4, Si−OH, and Si−O−Si vibrations. The broad band centered at and 3432 
cm−1 can be attributed to the O−H bonding vibration of adsorbed water and SiO-H groups. The 
spectrum of solid S1 showed the bands of [Ru(bpy)3]Cl2 at 1462, 1447, and 1421 cm−1,27 as well 
as the C−H in-plane bending vibration at 1233 cm−1 and the C− H out-of-plane bending vibration 
at 767 and 748 cm−1 corresponding to the benzimidazole residues attached to the mesoporous 
silica surface.28 The intensity of these bands was significantly reduced after incubation with 
AuCD because of the formation of supramolecular associations in solid S2. The presence of CD 
moieties in this solid was also confirmed by the band at 2934 cm−1, which could be ascribed to 
C−H groups in the oligosaccharide. 
The total content of [Ru(bpy)3]Cl2 in solid S2 was estimated as 15 mmol g−1 SiO2 by total alkaline 
hydrolysis of the capped nanomaterial. Moreover, thermogravimetric analysis revealed a 7.9% 
(w/w) of Au in calcined S2 (Figure S4). 
To assemble the integrated enzyme-controlled nanomachine S3, we first covalently modified 
glucose oxidase with 1-adamantane carboxylic acid yielding the GOx-ADA derivative. This 
modified enzyme was then layered on S2 support through the formation of host−guest 
supramolecular complexes with the free β-cyclodextrin residues at the AuCD surface. The 
resulting S3 nanodevice with a layer-by-layer design contained about 6 × 10−5 mg GOx-ADA per 
gram of nanoparticle, representing 1.27 U mg−1 S3. 
These nanoparticles were finally characterized by dynamic light scattering, and the results are 
shown in Figure S5 in Supporting Information. Functionalization with benzimidazol residues and 
loading with [Ru(bpy)3]Cl2 slightly increased the hydrodynamic diameter and reduced the zeta 
potential of solid S1 (114.2 nm, −41.0 mV), in comparison with the starting solid S0 (102.4 nm, 
−43.5 mV). Capping with AuCD lead to higher increase in the hydrodynamic diameter (179.7 nm) 
and a noticeable reduction in the zeta potential value (−21.7 mV) for solid S2. For the final solid 
S3, supramolecular immobilization of GOx-ADA caused a significant increase in the surface 
charge and hydrodynamic diameter, reaching values of −35.3 mV and 214.7 nm, respectively. 
 
Figure 3. (A) Kinetics of [Ru(bpy)3]Cl2 dye release from S3 in 20 mM Na2SO4, pH 7.5 (a) without and (b) with addition 
of glucose at a 50 mM final concentration. (B) Effect of glucose concentration on the normalized release of 
[Ru(bpy)3]Cl2 from S3 after 60 min of incubation. 
S3 nanomachine was tested for the on-command controlled delivery of the [Ru(bpy)3]Cl2 dye. In 
a typical release assay, 6 mg of S3 were suspended in 3 mL of 20 mM Na2SO4 solution at pH 7.5, 
and were shaken over time at 25 °C. Aliquots were periodically taken, centrifuged to remove the 
nanomaterial, and the absorbance 454 nm was then measured. As trigger for [Ru(bpy)3]Cl2 
release, 50 mM D-glucose was employed. As control, a similar assay was executed in parallel, 
but without addition of D-glucose. 
As Figure 3A illustrates, a negligible release of [Ru(bpy)3]Cl2 was observed in the absence of 
glucose, suggesting S3 nanomachine is still tightly capped. On the contrary, the addition of 
glucose resulted in the opening of pores in S3 producing a subsequent cargo delivery. This 
behavior can be explained by the enzymatic transformation of glucose to gluconic acid, with a 
consequent drop in pH at the microenvironment of the nanomachine. This acid media causes 
protonation of the benzimidazole moieties at the nanomachine surface, then disrupting the 
supramolecular complexes with AuCD and inducing [Ru(bpy)3]Cl2 release. 
 
Figure 4. Effect of different sugars (a: blank; b: glucose; c: sucrose; d: fructose; e: lactose; f: galactose; g: ribose; h: 
mannose; i: 2-deoxy-D- glucose; j: lactulose) at 50 mM concentration, on the normalized release of [Ru(bpy)3]Cl2 from 
S3 after 60 min incubation. 
To confirm this opening mechanism, we measured pH in both control and releasing systems. pH 
of the incubating media remained unchanged in the control experiment, but changed from 7.5 
to ca. 5.2 after incubation with glucose. In addition, suspensions of S3 were heated at 100 °C for 
10 min to inactivate the immobilized enzyme, and were further incubated with glucose. In this 
case, no appreciable dye release was observed from this thermal inactivated sample after 24 h 
of incubation, confirming that the opening mechanism was mediated by the glucose oxidase 
catalyzed reaction in the presence of glucose. This mechanism may be of interest for the design 
of glucose-triggered cargo delivery nanodevices able to detect fluctuations in blood glucose 
concentrations and release a cargo though a self-regulated process, which is still a challenge.16,20 
Figure 3B reports the dye release response of S3 nanodevice after 60 min incubation at pH 7.5 
with different concentrations of D-glucose. Null or negligible release of the encapsulated dye 
molecules was observed at low D-glucose concentrations, but S3 exhibited a linear release 
response vs the logarithm of D- glucose concentration between 100 μM and 10 mM. 
To evaluate the specificity of this nanomachine, solid S3 was tested toward different sugars, and 
compared with the release response obtained toward glucose. As can been observed in Figure 
4, the S3 nanodevice released a high amount of Ru(bipy)3Cl2 dye after incubation with D-glucose, 
and a low degree of dye delivery was observed in the presence of other sugars such as sucrose, 
fructose, lactose, galactose, ribose and lactulose. Only mannose and 2-deoxy-D-glucose caused 
a relative high release when used as triggers. This behavior can be explained by the intrinsic 
selectivity of glucose oxidase, which can also slightly recognize these two monosaccharides as 
potential substrates.29 
 
Figure 5. Confocal microscopy images of HeLa cells (A) untreated and incubated with 50 μg/mL of S4 in the (B) 
presence and (C) absence of glucose. Images were acquired after 24 h of incubation from phase contrast (PhC), Doxo 
(DOX), Hoescht, and combined (Merge). 
It should be highlighted that solid S3 showed high storage stability, retaining the mesoporous 
morphology (Figure S6) and more than 92 of the initial enzymatic activity after 3 months of 
storage at 4 °C in 20 mM Na2SO4, pH 7.5.  
To evaluate the possibilities of this enzyme-controlled nanomachine for drug delivery, we 
prepared a new S4 nanodevice by loading the nanodevice with the cytotoxic doxorubicin (Doxo) 
in Doxo-saturated aqueous solution, instead of Ru(bipy)3Cl2 dye. The amount of Doxo loaded on 
the nanomachine was estimated spectrophotometrically as 0.5 μmol per gram of nanoparticles. 
It was further determined that the S4 nanomachine showed a similar release pattern for Doxo 
than those obtained for S3 filled with Ru(bipy)3Cl2 dye upon addition of glucose (Figure S7). 
Accordingly, this nanomachine was evaluated for on-command release of Doxo to HeLa cancer 
cells in ex vivo experiments. 
S4 was then evaluated toward HeLa cells under the premise that the nanocarrier can be 
internalized by the cells and the supramolecular gate-like ensemble remains closed until glucose 
is added. We also hypothesized that the immobilized enzyme remains active into the cell, and is 
able to induce a pH reduction at the microenvironment of the nanomachine after exposure to 
glucose, allowing intracellular release of Doxo and causing cell death. 
In a typical assay, HeLa cells were suspended in PBS supplemented with 10% fetal bovine serum 
and further incubated with a suspension of 50 μg/mL of S4 during 30 min. HeLa cells were then 
washed with PBS to eliminate uninternalized nanoparticles and then incubated either in the 
absence or in the presence of D-glucose. The release of Doxo from solid S4 was study by confocal 
microscopy, by tracking drug-associated fluorescence signal. Furthermore, Hoechst 33342 was 
employed to stain the nuclei in HeLa cancer cells. Figure 5 shows representative confocal images 
of phase 
contrast, Doxo (red), Hoescht (blue, for HeLa nuclei staining) and combined Doxo+Hoescht (red 
and blue) for untreated HeLa cells, as well as for cells initially treated with S4 and further 
incubated in the presence and the absence of D-glucose. Internalization of the nanodevice did 
not produce a noticeable drug release in the incubation media without D- glucose, suggesting 
that not unspecific Doxo delivery occurred in a large extent. Accordingly, weak and concentrated 
red fluorescence signals were observed, due to quenching of Doxo fluorescence by the 
nanoparticles. On the contrary, a clear and disperse red fluorescence was observed for those 
cells incubated with D-glucose, indicating that this monosaccharide triggered the release of the 
encapsulated Doxo molecules from the S4 nanomachine. 
Similar results were achieved by using fluorescence microscopy (Figure S8). It was also 
demonstrated that the nanoparticles and the release of Doxo were homogeneously distributed 
into the cells, as observed by high resolution confocal images (Figure S9). 
Cell viability assays were carried out on HeLa cells treated with S4 nanomachine during 24 h. In 
addition, WST-1 assay was employed as quantification method. As can be observed in Figure 6, 
solid S4 was not toxic for HeLa cancer cells, not causing noticeable cell death after internalization 
in the absence of D-glucose even at a concentration as high as 100 μg/mL. On the contrary, 
apoptotic cell death was observed for HeLa cancer cells treated with S4 in the presence of D-
glucose. 
 
Figure 6. Cell viability assay for HeLa cancer cells incubated for 24 h with 50 μg/mL and 100 μg/mL S4 in the 
presence (filled) and absence (open) of glucose, using the WST-1 assay. 
In this sense, an average of 53 and 64% of cells were dead after 24 h of incubation with S4 at 50 
and 100 μg/mL, respectively. As final remark, it should be highlighted that the release 
mechanism for this nanocarrier is driven by local changes in pH, here fuelled by the enzymatic 
transformation of glucose. 
Accordingly, it would be expected that changes in intracellular or blood pH, as well as the 
presence of autogenous glucose should impact on the release of the drug. In our experimental 
models, not specificity Doxo release was observed, suggesting that the intracellular pH or 
autogenous glucose concentration in HeLa cells not caused uncapping of the host−guest 
supramolecular nanovalves in solid S4. However, for practical application of this nanomaterial 
as autonomous drug delivery system, further in vivo experiments should be performed to 
evaluated the potential interfering effect of pH, glucose and blood components. 
In summary, here we reported the layer-by-layer supra- molecular assembly of a pH-sensitive 
and enzyme-controlled nanomachine for on-command release. This nanomachine, based on a 
benzimidazole-modified MSN capped with AuCD and powered by a glucose oxidase derivative, 
was able to deliver the encapsulated cargo in the presence of D-glucose. The nanomachine was 
also successfully used to release the anticancer drug Doxo in HeLa cancer cells. We can envision 
that these results can open new possibilities for the assembly of a large variety of enzyme-
controlled nanomachines for smart and controlled delivery by rational selection of capping 




Preparation S0. To prepare the starting MSN (S0), we placed 1.0 g of cetyltrimethylammonium 
bromide in a 1.0 L three-neck round- bottom flask, and 480 mL of double-distilled water were 
added.17 The surfactant was dissolved under sonication, and then 3.5 mL of 2.0 mol/L NaOH 
solution were added. The temperature of the mixture was adjusted to 80 °C and 5.0 mL 
tetraethoxysilane were added dropwise to the solution within 5 min under vigorous magnetic 
stirring. The mixture was allowed to react for 2 h. The resulting white solid was filtered, washed 
with water and methanol, and then dried in desiccator. To remove the surfactant template, the 
solid was finally calcined at 550 °C for 5 h. 
Preparation of S1. To prepare the dye-loaded benzimidazole- coated MSN (S1), we suspended 
500 mg of S0 and 300 mg (39.6 μmol) of Ru(bipy)3Cl2·6H2O in 25 mL of anhydrous acetonitrile 
and heated it at 120 °C in a Dean−Stark apparatus under Ar atmosphere to remove the adsorbed 
water.16 The mixture was stirred for 24 h at room temperature to load the dye into the MSN face 
pores. Afterward, an excess of (3-iodopropyl)trimethoxysilane (196 μL, 1 mmol) was added and 
the suspension was stirred for 5.5 h. The resulting solid was filtered off, washed two times with 
10 mL toluene. The solid was further dispersed in 40 mL of a saturated solution of benzimidazole 
in toluene containing triethylamine (benzimidazol and triethylamine in a 1:3 proportion) at 80 
°C. The suspension was refluxed and stirred during 72 h. The final orange solid (S1) was filtered 
off, washed several times with acetonitrile, and dried at 70 °C overnight. 
Preparation of S2. AuCD were first prepared as previously reported,24,25 by using perthiolated β-
cyclodextrin as capping molecules and a β-cyclodextrin:HAuCl4 molar ratio of 1:5. Briefly, 50 mg 
of HAuCl4 were dissolved in 20 mL of DMSO, and the resulting solution was quickly mixed with 
another 20 mL of DMSO containing 76 mg of NaBH4 and 33 mg of perthiolated β-cyclodextrin. 
The mixture was kept under continuous stirring during 24 h, and then 40 mL of CH3CN was added 
to precipitate the nanoparticles. The solid was collected by centrifugation, and sequentially 
washed with 60 mL of CH3CN: DMSO (1:1 v/v) and 60 mL pf EtOH. The AuCD nanoparticles were 
finally isolated by centrifugation and dried under vacuum until use. 
To assemble the AuCD-capped nanodevice, we dispersed 30 mg of solid S1 in 5 mL of 0.1 M 
sodium phosphate buffer, pH 7.5, and further mixed it with 5 mL of the same buffer containing 
75 mg of AuCD and 20 mg of Ru(bipy)3Cl2·6H2O. The mixture was stirred overnight at room 
temperature, then centrifuged and the solid was washed several times with 0.1 M sodium 
phosphate buffer, pH 7.5, and dried in a desiccator. 
Preparation of S3. GOx-ADA (specific activity: 0.93 U/mg) was first synthesized as previously 
described.16 Briefly, 2.5 mg of 1- adamantylamine (0.016 mmol) and 3 mg of 1-ethyl-3-(3-
dimethyla- mino-propyl)carbodiimide hydrochloride (0.016 mmol) were dispersed in 3 mL of 0.1 
M sodium phosphate buffer, pH 6.0. To this solution was added 1.6 mg of glucose oxidase (from 
A. niger, Type VII, Sigma-Aldrich) dissolved in 0.3 mL of the same buffer. The reaction mixture 
was stirred for 2 h at room temperature and further 20 h at 4 °C. The solution was then dialyzed 
vs 0.1 M sodium phosphate buffer, pH 7.0, and concentrated by 30K Amicon Ultra-05 centrifugal 
filter devices (EMD Millipore Corporation). 
To prepare the enzyme-functionalized nanomachine, we dispersed 30 mg of solid S2 in 4 mL of 
0.1 M sodium phosphate buffer, pH 7.5, at 4 °C, and then 156 μL of a 60 mg/mL GOx-ADA 
solution were added. The mixture was stirred at 4 °C overnight, further centrifuged, and the 
resulting solid was washed twice with cold buffer. Solid S3 was then suspended in 10 mM sodium 
phosphate buffer, pH 7.5, at a 30 mg/mL final concentration and kept at 4 °C until use. 
Release Assays. A 2.0 mg/mL suspension of S3 in 20 mM Na2SO4, pH 7.5, was freshly prepared. 
For each batch experiment, aliquots of 3 mL were employed. To monitor the ruthenium complex 
release, we removed 0.3 mL of the suspension at scheduled times, then centrifuged, and the 
delivered cargo was registered via the Ru(bipy)3Cl2· absorbance at 453 nm. To trigger the release 
mechanism, we employed glucose at a 50 mM final concentration   as INPUT signal. 
Cell Culture Conditions. HeLa human cells were grown and maintained as previously described.6  
WST-1 Cell Viability Assay. This assay was performed as previously described by using solid S4 in 
DMSO at final concentrations of 50 μg/mL and 100 mg/mL.6  
Live Confocal Microscopy. Live confocal microscopy experiments were performed as described,6 
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